在Takotsubo综合征诱导的心脏性休克中,血管活性-内热学评分
Marco Tomasino1, Sofía Vila-Sanjuán2, Ravi Vazirani3
1Department of Cardiology, Hospital Universitari Vall d'Hebron, Barcelona, Spain.
Medicina intensiva
|April 18, 2025
概括
血管活性-内热性评分 (VIS) 预测,Takotsubo综合征 (TTS) 患有心脏性休克 (CS) 的患者的结果会更差. 较高的VIS分数与这些重症患者的死亡率和并发症增加有关.
科学领域:
- 心脏病学 心脏病学
- 关键护理医学 关键护理医学
- 临床研究 临床研究
背景情况:
- 塔科特苏博综合征 (TTS) 可以导致心脏性休克 (CS),这是一种危及生命的疾病.
- 血管活性-内热性评分 (VIS) 用于量化严重病患者需要血液动力学支持的需求.
- 由CS复杂的TTS的预后标志物对于风险分层和管理至关重要.
研究的目的:
- 评估血管活性-内热学评分 (VIS) 的预后意义,在患有塔科苏博综合征 (TTS) 与同时发生心脏性休克 (CS) 的患者中.
- 在这个患者群体中,确定VIS tertiles与短期 (30天) 和长期 (1年) 死亡率之间的关联.
主要方法:
- 使用RETAKO多中心注册表 (2003-2022) 的数据进行了回顾性队列分析.
- 分析了1591名TTS患者,重点关注412名 (26%) 患有CS.
- 基于在CS诊断后24小时内最大的血管活性和无otropic药物剂量计算VIS.
主要成果:
- 与最低三位数相比,VIS三位数最高的患者的30天 (HR 8.80) 和1年 (HR 4.55) 死亡率显著更高.
- 较高的VIS与增加的并发症有关,包括急性损伤,严重出血和需要机械循环支持.
- 在VIS第三类中,住院死亡率逐渐增加:4% (低),14% (中) 和47% (高) (p < 0.001).
结论:
- 血管活性-内热学评分 (VIS) 是一个有价值的预后工具,用于Takotsubo综合征 (TTS) 的患者,并由心脏性休克 (CS) 复杂化.
- 升高的VIS与短期和长期不良结果密切相关,包括增加死亡率和并发症.
- 需要对高VIS患者的因果途径和治疗优化进行进一步的研究.
相关概念视频
Heart Failure Drugs: Inotropic Agents
405
Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
405
Imbalances in Cardiac Output
1.2K
The heart's primary function is to pump blood throughout the body, maintaining a balance between blood sent out (cardiac output) and blood returning (venous return). If this balance is disrupted, it can result in congestive heart failure (CHF), a severe condition where the heart becomes an inefficient pump, leading to inadequate blood circulation.
CHF can occur due to the failure of either side of the heart. Left-side failure leads to pulmonary congestion—the right side continues to...
CHF can occur due to the failure of either side of the heart. Left-side failure leads to pulmonary congestion—the right side continues to...
1.2K
Heart Failure Drugs: β-Blockers
260
β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation,...
260
Cardiac Output II: Effect of Stroke Volume on Cardiac Output
519
Cardiac output (CO), the amount of blood the heart pumps per minute, is a parameter in cardiovascular physiology determined by stroke volume and heart rate. Stroke volume, the amount of blood pushed from one of the ventricles per heartbeat, is influenced by preload, afterload, and contractility.
Preload
Preload refers to the initial elongation of the cardiac myocytes before contraction and is related to the volume of blood filling the heart at the end of diastole, or end-diastolic volume. The...
Preload
Preload refers to the initial elongation of the cardiac myocytes before contraction and is related to the volume of blood filling the heart at the end of diastole, or end-diastolic volume. The...
519
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
305
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
305
Antianginal Drugs: Nitrates and β-Blockers
437
In cardiovascular health, antianginal drugs combat angina pectoris — a condition marked by chest pain owing to diminished blood flow to the heart.
Organic nitrates, such as nitroglycerin, play a pivotal role. Once metabolized, they liberate nitric oxide, a molecular marvel. Nitric oxide triggers guanylyl cyclase and augments cGMP production. This biochemical cascade orchestrates the relaxation of vascular smooth muscles, ushering in vasodilation and enhancing coronary blood flow....
Organic nitrates, such as nitroglycerin, play a pivotal role. Once metabolized, they liberate nitric oxide, a molecular marvel. Nitric oxide triggers guanylyl cyclase and augments cGMP production. This biochemical cascade orchestrates the relaxation of vascular smooth muscles, ushering in vasodilation and enhancing coronary blood flow....
437


